Ironwood spies new frontier for $1B GLP-2 analog in exploratory phase 2 rare disease trial

Ironwood Pharmaceuticals’ stargazing has identified a new frontier for apraglutide by generating early clinical evidence that the GLP-2 analog plays nicely with Incyte’s Jakafi in a rare disease. The company acquired the molecule last year through its $1 billion takeover of VectaBio.